|
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.
|
|
[2] Chinese society of infectious diseases,Chinese society of hepatology. The expert consensus on functional cure of chronic hepatitis B[J]. J Chin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]．临床肝胆病杂志，2019,35(8):1693-1701.
|
|
[3] LI L,LYU J,XIAO M,et al. Clinical characteristics of severe thrombocytopenic purpura induced by interferon in 27 cases[J].World Chin J Dig,2009,17(11):1147-1151.(in Chinese)李丽，闾军，肖默，等．干扰素诱导的严重血小板减少性紫癜临床特点分析27例[J]．世界华人消化杂志，2009,17(11):1147-1151.
|
|
[4] Thrombosis and hemostasis group,hematology branch,Chinese medical association. Chinese expert consensus on diagnosis and treatment of thrombotic thrombocytopenic purpura(2012 edition)[J]. J Chin Hematol,2012,33(11):983-984.(in Chinese)中华医学会血液学分会血栓与止血学组．血栓性血小板减少性紫癜诊断与治疗中国专家共识(2012年版)[J]．中华血液学杂志，2012,33(11):983-984.
|
|
[5] LI B,GAO R,LI R,et al. Study on the methods to determine the association of adverse reactions/adverse events in drug clinical trials[J]. Chin J New Drugs,2014,23(12):1465-1470.(in Chinese)李博，高蕊，李睿，等．药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]．中国新药杂志，2014,23(12):1465-1470.
|
|
[6] TERRAULT NA,LOK A,MCMAHON BJ,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
|
[7] ZHANG Y,ZHANG L,CHEN M,et al. Clinical analysis of 10cases of refractory/recurrent thrombocytopenic purpura treated with rituximab combined regimen[J]. J Chin Hematol,2018,39(10):855-858.(in Chinese)张炎，张路，陈苗，等．含利妥昔单抗联合方案治疗难治/复发血栓性血小板减少性紫癜10例临床分析[J]．中华血液学杂志，2018,39(10):855-858.
|
|
[8] WAZNY LD,ARIANO RE. Evaluation and management of druginduced thrombocytopenia in the acutely ill patient[J]. Pharmacotherapy,2000,20(3):292-307.
|
|
[9] IYODA K,KATO M,NAKAGAWA T,et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C[J]. J Gastroenterol,1998,33(4):588-592.
|
|
[10] KUNDRA A,WANG JC. Interferon induced thrombotic microangiopathy(TMA):Analysis and concise review[J]. Crit Rev Oncol Hematol,2017,112:103-112.
|
|
[11] DEUTSCH M,MANESIS EK,HADZIYANNIS E,et al. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b[J]. Scand J Gastroenterol,2007,42(3):408-409.
|
|
[12] PODDAR N,WANG JC. Thrombotic thrombocytopenic purpura in a patient with interferon treated hepatitis C successfully treated with rituximab[J]. Hematol Rep,2013,5(1):5-7.
|
|
[13] DING L,QIAN Z,ZHANG YH,et al. One case of thrombotic thrombocytopenic purpura during treatment with hepatitis B interferon[J]. J Chin Hematol,2016,37(12):1037.(in Chinese)丁磊，钱琤，张宇浩，等．乙型肝炎干扰素治疗期间合并血栓性血小板减少性紫癜一例[J]．中华血液学杂志，2016,37(12):1037.
|
|
[14] Expert committee on clinical management of therapeutic side effects of interferon in patients with chronic viral hepatitis.Chronic viral hepatitis patients with interferon treatment of adverse reactions clinical treatment experts consensus[J/CD].Chin J Exp Clin Infect Dis(Electronic Edition),2014,8(1):96-101.(in Chinese)慢性病毒性肝炎患者干扰素α治疗不良反应临床处理专家委员会．慢性病毒性肝炎患者干扰素α治疗不良反应临床处理专家共识[J/CD]．中华实验和临床感染病杂志(电子版)，2014,8(1):96-101.
|
|
[15] ZHANG WH,ZHANG DZ,DOU XG,et al. Expert consensus on the treatment of chronic hepatitis B with peg interferon beta[J]. Chin J Hepatol,2017,25(9):678-686.(in Chinese)张文宏，张大志，窦晓光，等．聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]．中华肝脏病杂志，2017,25(9):678-686.
|
DownLoad: